Ovarian suppression for early breast cancer
Authors:
- Nicholas WilckenNWNicholas Wilcken
- Martin StocklerMSMartin Stockler
- 1 May 2007
- journal article
- editorial
- Published by Elsevier in The Lancet
- Vol. 369 (9574) , 1668-1670
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trialsThe Lancet, 2007
- Patients’ preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile?British Journal of Cancer, 2005
- Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now?Annals of Oncology, 2005
- What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?The Lancet Oncology, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Adjuvant Endocrine Therapy for Premenopausal Women With Early Breast CancerJournal of Clinical Oncology, 2005
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast CancerNew England Journal of Medicine, 2003
- ON THE TREATMENT OF INOPERABLE CASES OF CARCINOMA OF THE MAMMA: SUGGESTIONS FOR A NEW METHOD OF TREATMENT, WITH ILLUSTRATIVE CASES.1The Lancet, 1896